One Shot Could Treat Knee Arthritis for Weeks

Millions of people with knee arthritis may soon need far fewer painful joint injections, thanks to a gel that turns into a medication reservoir right inside the body.

Researchers at the University at Buffalo have developed an injectable hydrogel that transforms from liquid to semisolid at body temperature. Once inside an arthritic joint, it acts as both a lubricant and a slow-release drug delivery system for several weeks.

The innovation tackles one of the biggest frustrations in osteoarthritis care. Current treatments like pain relievers and steroids wash out of joints quickly, forcing patients to return for repeated injections that offer only temporary relief. Many of these treatments also fail to slow the disease itself.

The new gel solves this problem by trapping medication inside tiny carriers that release gradually over time. This keeps drugs concentrated exactly where they're needed rather than spreading throughout the body and causing side effects elsewhere.

The injection starts as a liquid, making it easy to deliver with a minimally invasive procedure. Within moments of entering the joint, body heat triggers it to become a smooth, slippery material that cushions damaged cartilage while dispensing medicine.

The Ripple Effect

Beyond convenience, this technology opens doors to treatments that were previously impractical. The gel can carry high concentrations of poorly soluble drugs that could actually modify the disease process, not just mask symptoms.

Researchers have already validated the approach using a compound that targets cellular aging and inflammation, two key drivers of osteoarthritis. The platform can be adapted to deliver different therapeutic compounds depending on what each patient needs.

The system was designed with real-world use in mind. It uses biocompatible materials that already have regulatory acceptance, potentially speeding the path from laboratory to clinic.

While knee osteoarthritis is the primary target, the same technology could help treat other degenerative joint conditions. Scientists see potential applications for shoulder injuries, spinal disc problems, and post-traumatic arthritis in younger patients.

For the 32 million Americans struggling with osteoarthritis, this could mean trading weekly or monthly doctor visits for a single quarterly injection that both soothes joints and fights disease progression.

One shot doing the work of many could transform how we care for one of the world's most common causes of chronic pain.